Barghouthy Y, Corrales M, Doizi S, Somani B, Traxer O
World J Urol. 2020; 39(7):2417-2426.
PMID: 33052484
DOI: 10.1007/s00345-020-03466-8.
Robertson W
Urolithiasis. 2016; 45(1):43-56.
PMID: 27900407
DOI: 10.1007/s00240-016-0953-y.
Khan S, Pearle M, Robertson W, Gambaro G, Canales B, Doizi S
Nat Rev Dis Primers. 2016; 2:16008.
PMID: 27188687
PMC: 5685519.
DOI: 10.1038/nrdp.2016.8.
Siener R
Urolithiasis. 2015; 44(1):51-6.
PMID: 26614113
DOI: 10.1007/s00240-015-0844-7.
Phillips R, Hanchanale V, Myatt A, Somani B, Nabi G, Biyani C
Cochrane Database Syst Rev. 2015; (10):CD010057.
PMID: 26439475
PMC: 9578669.
DOI: 10.1002/14651858.CD010057.pub2.
The role of lithium carbonate and lithium citrate in regulating urinary citrate level and preventing nephrolithiasis.
Zhang X, Aggarwal P, Li X, Oakman C, Wang Z, Rodriguez R
Int J Biomed Sci. 2013; 5(3):215-22.
PMID: 23675140
PMC: 3614779.
Urolithiasis in children: medical approach.
Copelovitch L
Pediatr Clin North Am. 2012; 59(4):881-96.
PMID: 22857835
PMC: 3426770.
DOI: 10.1016/j.pcl.2012.05.009.
A hypothesis of calcium stone formation: an interpretation of stone research during the past decades.
Tiselius H
Urol Res. 2011; 39(4):231-43.
PMID: 21246193
DOI: 10.1007/s00240-010-0349-3.
Genetic basis of renal cellular dysfunction and the formation of kidney stones.
Khan S, Canales B
Urol Res. 2009; 37(4):169-80.
PMID: 19517103
PMC: 3625631.
DOI: 10.1007/s00240-009-0201-9.
High calcium concentration and calcium oxalate crystals cause significant inaccuracies in the measurement of urinary osteopontin by enzyme linked immunosorbent assay.
Thurgood L, Grover P, Ryall R
Urol Res. 2008; 36(2):103-10.
PMID: 18478219
DOI: 10.1007/s00240-008-0139-3.
Effects of trace metals on the inhibition of calcium oxalate crystallization.
Munoz J, Valiente M
Urol Res. 2005; 33(4):267-72.
PMID: 15937709
DOI: 10.1007/s00240-005-0468-4.
Synergism between the brushite and hydroxyapatite urinary crystallization inhibitors.
Costa-Bauza A, Barcelo C, Perello J, Grases F
Int Urol Nephrol. 2003; 34(4):447-51.
PMID: 14577482
DOI: 10.1023/a:1025671019653.
Role of biomolecules from human renal stone matrix on COM crystal growth.
Aggarwal S, Tandon C, Forouzandeh M, Singla S, Kiran R, Jethi R
Mol Cell Biochem. 2000; 210(1-2):109-19.
PMID: 10976764
DOI: 10.1023/a:1007109120558.
Characterization of protein components of human urinary crystal surface binding substance.
Honda M, Yoshioka T, Yamaguchi S, Yoshimura K, Miyake O, Utsunomiya M
Urol Res. 1997; 25(5):355-60.
PMID: 9373917
DOI: 10.1007/BF01294665.
Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation.
Ryall R
World J Urol. 1997; 15(3):155-64.
PMID: 9228722
DOI: 10.1007/BF02201852.
Hypocitraturia in patients with urolithiasis.
Akcay T, Konukoglu D, Celik C
Arch Dis Child. 1996; 74(4):350-1.
PMID: 8669940
PMC: 1511487.
DOI: 10.1136/adc.74.4.350.
Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization.
Atmani F, Lacour B, Drueke T, Daudon M
Urol Res. 1993; 21(1):61-6.
PMID: 8456540
DOI: 10.1007/BF00295195.
A new approach to studying inhibitors of calcium oxalate crystal growth.
Hennequin C, Lalanne V, Daudon M, Lacour B, Drueke T
Urol Res. 1993; 21(2):101-8.
PMID: 8389069
DOI: 10.1007/BF01788827.
The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin.
Worcester E, Sebastian J, Hiatt J, Beshensky A, Sadowski J
Calcif Tissue Int. 1993; 53(4):242-8.
PMID: 8275352
DOI: 10.1007/BF01320909.
Aspects of the influence of magnesium ions on the formation of calcium oxalate.
WUNDERLICH W
Urol Res. 1981; 9(4):157-61.
PMID: 7269002
DOI: 10.1007/BF00264820.